Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Discussion in 'Men's Economics' started by Michael Scally MD, Mar 4, 2013.

  1. Michael Scally MD

    Michael Scally MD Doctor of Medicine

    Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)
    Ironwood Pharmaceuticals

    Helping Tie Up A Peptide Drug’s Loose Ends
    Case Study #1: Ironwood works with peptide makers and others to turn its cross-linked molecule into a drug
    Helping Tie Up A Peptide Drug’s Loose Ends | March 4, 2013 Issue - Vol. 91 Issue 9 | Chemical & Engineering News

    “Because linaclotide acts as a signal in this process, Ironwood saw it as a treatment for chronic idiopathic constipation and irritable bowel syndrome with constipation in adults. In the U.S., as many as 35 million people suffer from the first problem and another 13 million from the second. Linaclotide was the first, and to date only, GC-C agonist approved in the U.S., according to the firm. Before the approval, physicians had few therapies to offer these patients other than standard over-the-counter remedies. By 2021, the drug could have annual sales of $1.2 billion, predicts the market research firm Decision Resources.”